Haima Therapeutics integral part of DAPRA FSHARP $46M project to develop a shelf-stable whole blood surrogate

 

FEBRUARY 20, 2023. DARPA selected a team for its Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program. The program will provide $46 million to a number of organizations, including Haima Therapeutics LLC (Haima), and led by the University of Maryland, Baltimore (UMB) to develop a field-deployable, shelf-stable whole blood equivalent that can be used to resuscitate trauma patients.

The DARPA FSHARP program aims to develop a shelf-stable whole blood equivalent with the same key functions as blood: deliver oxygen, stop bleeding, and replace volume when blood is not available. Haima’s role is focused on the hemorrhage control component by providing a platelet-inspired hemostatic agent, which is already in pre-clinical development. 

Robust clinical studies have demonstrated that early transfusion of whole blood (WB) or controlled ratio of blood components (platelets + RBC + plasma) are associated with significant improvement of survival in severely injured patients. However, WB or blood component products are of very limited availability due to a variety of logistical challenges, especially in emergency pre-hospital settings like the battlefield or civilian site of injury. This leads to a significant number of preventable deaths from traumatic injury. Products like the whole blood surrogate being developed may provide a ‘bridge technology’ for point-of-injury on demand hemostatic resuscitation that could have a tremendous benefit in saving lives.

Haima will work closely with Case Western Reserve University (CWRU) and the consortium partners to develop a hemostatic agent that works safely and effectively in combination with the oxygen carrying and plasma components. The initial partners include Charles River Laboratories, KaloCyte Inc., Latham Biopharm Group, Ohio State University, Pumas-AI Inc., Southwest Research Institute, Teleflex Incorporated, University of California San Diego, and University of Pittsburgh.

This work builds on Haima’s multi-year collaboration with KaloCyte, UMB, and Teleflex evaluating the potential co-administration of its synthetic platelet hemostatic technology with lyophilized plasma and a novel red blood cell surrogate supported by the Department of Defense (DoD).

This exciting news is getting national coverage. Here’s just a few of the notable articles, videos, and podcast:

About Haima Therapeutics

Haima Therapeutics is a pre-clinical stage biopharma company developing platelet-inspired technologies for the treatment of bleeding and a variety of blood-related diseases. Haima’s initial focus is on platelet’s primary focus is on developing bio-inspired therapies to mitigate active bleeding and bleeding risks after traumatic injury, surgery, and thrombocytopenia. Haima’s lead technology is called SynthoPlate, a novel, fully-synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms. Haima is currently raising Series A funds, and interested investors should contact Michael Bruckman at mbruckman@haimatherapeutics.com.

Learn more at www.haimatherapeutics.com, follow us on twitter @HaimaThr, or email us at info@haimatherapeutics.com